Skip to main content
REVB
NASDAQ Life Sciences

Revelation Cuts Gemini Kidney-Injury Trial Budget to ~$7M From ~$60M

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.2
Mkt Cap
$2.915M
52W Low
$3.08
52W High
$40.6
52W Position info
36% above low
Off High info
90% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

REVB sits 36% above its 52-week low of $3.08.

Summary

Revelation plans a Phase 2a study of Gemini in stage 2 or 3 acute kidney injury starting in early 2027, with topline data expected in late 2027. The study is budgeted at roughly $7M versus roughly $60M under the prior approach, cutting expected development spending by about $53M. That matters because the company held just $9.1M of cash at September 30, 2026 and its 10-Q warned it cannot fund a full year of operations — the cheaper design makes the program more financeable, though the $7M still consumes most of the current cash balance. This is a plan reset, not new clinical data; the stock remains a micro-cap after the 1-for-7 reverse split effective October 20, 2026. Study initiation and how the company funds it are the next hard checkpoints, with topline data not due until late 2027.

At the time of this announcement, REVB was trading at $4.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $3.08 to $40.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

REVB - Latest Insights

REVB
Nov 05, 2026, 5:29 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $3.56
Real-time Price: $3.79 info
Change: +$0.230 (+6%) info
Market Cap: $2.59M info
REVB
Nov 05, 2026, 5:23 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.56
Real-time Price: $3.79 info
Change: +$0.230 (+6%) info
Market Cap: $2.59M info
REVB
Oct 16, 2026, 9:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.7622
Real-time Price: $3.79 info
Change: Reverse Stock Split info
Market Cap: $2.59M info
REVB
Aug 06, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $3.79 info
Change: Reverse Stock Split info
Market Cap: $2.59M info
REVB
Aug 06, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.12
Real-time Price: $3.79 info
Change: Reverse Stock Split info
Market Cap: $2.59M info